Survival and Response After Peptide Receptor Radionuclide Therapy With [90Y-DOTA0,Tyr3]Octreotide in Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors
Top Cited Papers
- 1 April 2006
- journal article
- research article
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 36 (2) , 147-156
- https://doi.org/10.1053/j.semnuclmed.2006.01.001
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Prospective, Randomized, Multicenter Trial on the Antiproliferative Effect of Lanreotide, Interferon Alfa, and Their Combination for Therapy of Metastatic Neuroendocrine Gastroenteropancreatic Tumors—The International Lanreotide and Interferon Alfa Study GroupJournal of Clinical Oncology, 2003
- A 5‐decade analysis of 13,715 carcinoid tumorsCancer, 2003
- The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?Annals of Oncology, 2002
- Treatment of Neuroendocrine GEP Tumours with Somatostatin AnaloguesDigestion, 2000
- Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinomaCancer, 2000
- Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinomaCancer, 1999
- Radiotherapy with a Radiolabeled Somatostatin Analogue, [111In‐DTPA‐d‐Phe1]‐OctreotideAnnals of the New York Academy of Sciences, 1994
- Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell CarcinomaNew England Journal of Medicine, 1992
- Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasmsCancer, 1991
- Streptozocin Alone Compared with Streptozocin plus Fluorouracil in the Treatment of Advanced Islet-Cell CarcinomaNew England Journal of Medicine, 1980